Related Experiment Video
Updated: Mar 28, 2026
Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
Published on: October 13, 2017
EFFECT OF INTRAOPERATIVE MITOMYCIN-C APPLICATION IN OUTCOME OF EXTERNAL DACRYOCYSTORHINOSTOMY
Background:
Patients develop postoperative fibrosis at the site of operation after dacryocystorhinostomy (DCR) which results in impairment of the osteum patency. This quasi-experimental study was undertaken to determine the role of intraoperative Mitomycin C (MMC) application in maintaining postoperative patency of the osteum.
Methodology:
The present study was conducted at the Eye department of Ayub Medical College, Abbottabad on patients in whom routine DCR was indicated. Subjects were divided into mitomycin C (Test) and non mitomycin C (Control) groups. In test group, Mitomycin C was applied to the anastomosed flaps and osteotomy site for 30 minutes. Postoperative patients were followed for up to 6 months and outcome of patency was documented.
Results:
A.total of 73 patients were included, divided into test (30) and control (43) groups. An overall success rate of 86.3% was obtained for patent ostia; this was based on 96.67% success in test group compared to 79.1% in the control group (p=0.031).
Conclusion:
Intraoperative application of Mitomycin-C significantly improves the success rate in external dacryocystorhinostomy.
Insights
Intraoperative Mitomycin C (MMC) application during dacryocystorhinostomy (DCR) significantly improves the success rate of maintaining osteum patency. This method enhances surgical outcomes by reducing postoperative fibrosis.
Area of Science:
- Ophthalmology
- Surgical Innovation
- Medical Research
Background:
- Postoperative fibrosis following dacryocystorhinostomy (DCR) can impair osteum patency.
- Maintaining osteum patency is crucial for successful DCR outcomes.
- Fibrosis is a common complication affecting surgical success.
Purpose of the Study:
- To evaluate the efficacy of intraoperative Mitomycin C (MMC) in preventing postoperative fibrosis.
- To determine if MMC application improves osteum patency rates after DCR.
- To assess the role of MMC in enhancing long-term DCR success.
Main Methods:
- A quasi-experimental study involving 73 patients undergoing DCR.
- Patients were divided into two groups: Mitomycin C (Test) and Control (No MMC).
- MMC was applied intraoperatively to the surgical site in the test group, with a 6-month follow-up for patency assessment.
Main Results:
- An overall success rate of 86.3% for patent ostia was achieved.
- The test group (MMC) demonstrated a significantly higher success rate (96.67%) compared to the control group (79.1%).
- The difference in success rates between groups was statistically significant (p=0.031).
Conclusions:
- Intraoperative Mitomycin C application significantly enhances the success rate of external dacryocystorhinostomy.
- MMC is an effective agent in maintaining postoperative osteum patency.
- The study supports the use of MMC to improve DCR surgical outcomes.
